Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06895070

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UC San Diego Health, La Jolla, California, United States

Loading trial locations.

About this study

This is a continuation of the PRESERVE IDE trial to provide additional data evaluating the safety and effectiveness of the XVIVO Heart Assist Transport System. The PRESERVE Continued Access Protocol (CAP) will utilize the XHAT System to preserve donor hearts that may not meet current standard donor heart acceptance criteria with the intention of these hearts being transplanted. The CAP has been implemented to allow patients and physicians access to the XHAT System while a Post-Market Approval (PMA) application is being submitted and reviewed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Recipient:

To be eligible to participate in this study, a recipient must meet all the following criteria:

  • Age ³18 years.
  • Signed informed consent form (ICF).
  • Listed for heart transplantation.

Exclusion criteria

Recipient:

  • Previous solid organ or bone marrow transplantation.
  • Requires a multi-organ transplant.
  • Subject is enrolled and ongoing in another investigational pharmaceutical or medical device clinical trial (Exception: observational studies are permitted).
  • Subject is on mechanical circulatory support pre-transplant other than durable LVAD, Impella or intra-aortic balloon pump (IABP).
  • History of complex congenital heart disease ie: single ventricle physiology (per Investigator's discretion and XVIVO review).
  • Subject on renal replacement therapy/dialysis.
  • Ventilator dependence (subject is intubated at time of transplant/unable to provide consent or re-affirmation of consent).
  • Sensitized participants meeting any of the following:
  • Participant with calculated Panel Reactive Antibody (cPRA) greater than 50%
  • Participant undergoing any desensitization treatment (also with cPRA less than 50%)
  • Participant with a positive prospective crossmatch and/or a positive virtual cross match

Donor Inclusion Criteria:

To be eligible to participate in this study, the donor heart must meet the following criteria:

  • Estimated Cross Clamp Time ≥4 hours OR
  • Estimated Cross Clamp ≥ 2 hours AND

Any one or more of the following:

  • Age ≥50 years
  • LVEF 40% - 50% at time of provisional acceptance. (Refer to section 6.3.4 for definition of provisional acceptance).
  • Down-time ≥20 minutes
  • Hypertrophy septal thickness >12 - ≤16mm
  • Angiographic luminal irregularities with no significant CAD OR 1) Donation after Circulatory Death (DCD)

Donor Exclusion Criteria:

Donor hearts that meet any of the following criteria will be excluded from transplantation in this study:

  • Unstable hemodynamics requiring high-dose inotropic support.
  • Significantly abnormal coronary angiogram defined as CAD > 50% stenosis of one or more vessels or if the donor heart exhibits any contusions, structural damage, gross abnormalities, or palpable CAD on final examination.
  • Moderate to severe cardiac valve pathology.
  • Investigator's clinical decision to exclude from trial.
  • Previous sternotomy.

Treatment and study plan

Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)

Device

Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)

Primary outcomes

  1. The percentage of patient treatment success rate

    Time frame: 30 days post transplantation

    The percentage of patient treatment success rate at 30-days post transplantation. The treatment success is defined as freedom from treatment failure.

  2. The percentage of patient survival

    Time frame: Post-operative Day 365.

    The percentage of patient survival at 365 days from the date of transplant. The long-term safety success is defined as survival.

Study contacts

Contact information is provided by the study sponsor or research team.

Amanda Carpenter

CONTACT

[email protected]

617-283-8332

Jen Ruel

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

XVIVO Perfusion

Industry

Registry information

Official study title

PRESERVE CAP: A Prospective, Multi-Center, Single-Arm, Open-Label Study of Hearts Transplanted After Non-Ischemic Heart Preservation From Extended Donors Continued Access Protocol

Acronym: NIHP-CAP-001

Important dates

Study start
2025
Primary completion
2026
Study completion
2031
First posted
Mar 26, 2025
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.